Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLC
Authors:
- 1 December 1995
- journal article
- clinical trial
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 14 (1-2) , 213-220
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous PolyposisNew England Journal of Medicine, 1993
- Effects of Long-term Sulindac Therapy on Colonic PolyposisAnnals of Internal Medicine, 1991
- Sulindac causes regression of rectal polyps in familial adenomatous polyposisGastroenterology, 1991
- Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkageGastroenterology, 1991
- Sulindac for polyposis of the colonThe American Journal of Surgery, 1989
- Biotransformation of sulindac in end-stage renal diseaseClinical Pharmacology & Therapeutics, 1987
- Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindacClinical Pharmacology & Therapeutics, 1985
- Biliary secretion of sulindac and metabolites in manBiopharmaceutics & Drug Disposition, 1983
- Sulindac disposition when given once and twice dailyClinical Pharmacology & Therapeutics, 1982
- The disposition of sulindacClinical Pharmacology & Therapeutics, 1977